CA2494544A1 - Method of treating osteoarthritis - Google Patents

Method of treating osteoarthritis Download PDF

Info

Publication number
CA2494544A1
CA2494544A1 CA002494544A CA2494544A CA2494544A1 CA 2494544 A1 CA2494544 A1 CA 2494544A1 CA 002494544 A CA002494544 A CA 002494544A CA 2494544 A CA2494544 A CA 2494544A CA 2494544 A1 CA2494544 A1 CA 2494544A1
Authority
CA
Canada
Prior art keywords
pain
substituted
dimethyl
methyl
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494544A
Other languages
English (en)
French (fr)
Inventor
Joseph Anthony Cornicelli
Kenneth Stanley Kilgore
Drago Robert Sliskovic
Susan Elizabeth Bove
David Herbert Neideffer
Mark Charles Kowala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2494544A1 publication Critical patent/CA2494544A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002494544A 2002-08-22 2003-08-13 Method of treating osteoarthritis Abandoned CA2494544A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40525002P 2002-08-22 2002-08-22
US60/405,250 2002-08-22
PCT/IB2003/003664 WO2004017952A1 (en) 2002-08-22 2003-08-13 Method of treating osteoarthritis

Publications (1)

Publication Number Publication Date
CA2494544A1 true CA2494544A1 (en) 2004-03-04

Family

ID=31946834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494544A Abandoned CA2494544A1 (en) 2002-08-22 2003-08-13 Method of treating osteoarthritis

Country Status (13)

Country Link
EP (1) EP1539127A1 (https=)
JP (1) JP2006501238A (https=)
KR (1) KR20050058454A (https=)
CN (1) CN1678297A (https=)
AU (1) AU2003255937A1 (https=)
BR (1) BR0313883A (https=)
CA (1) CA2494544A1 (https=)
IL (1) IL166600A0 (https=)
MX (1) MXPA05001254A (https=)
PL (1) PL375742A1 (https=)
TW (1) TW200410677A (https=)
WO (1) WO2004017952A1 (https=)
ZA (1) ZA200501133B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105801A1 (en) * 2003-05-30 2004-12-09 Warner-Lambert Company Llc Animal model for the alleviation of pain using il-6
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
DE102008000237A1 (de) 2007-02-06 2008-08-07 Basf Se Phenol-Imidazolderivate zur Stabilisierung von polymerisationsfähigen Verbindungen
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
US8530420B2 (en) * 2008-12-16 2013-09-10 Kaohsiung Medical University Treatment of arthritis with parathyroid hormone
TWI382841B (zh) 2010-10-29 2013-01-21 Univ China Medical 用於抑制發炎之醫藥組合物
CA3059073A1 (en) * 2017-04-18 2018-10-25 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
JP2022505033A (ja) * 2018-10-18 2022-01-14 ジェムフィアー セラピューティクス インコーポレイテッド ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
CN114847223B (zh) * 2022-02-19 2023-11-07 昆明理工大学 一种建立oa食蟹猴模型的方法
US12208085B2 (en) * 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals
CN118750511A (zh) * 2024-06-24 2024-10-11 中南大学湘雅医院 多元酸镁盐及其水合物在制备治疗或/和减缓关节疼痛的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
SK10622002A3 (sk) * 2000-01-25 2003-07-01 Warner-Lambert Company Étery dikarboxylátu vápenatého, metódy ich výroby a ich využitie na liečbu vaskulárnych chorôb a diabetu
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

Also Published As

Publication number Publication date
IL166600A0 (en) 2006-01-15
TW200410677A (en) 2004-07-01
MXPA05001254A (es) 2005-06-08
CN1678297A (zh) 2005-10-05
BR0313883A (pt) 2005-07-19
WO2004017952A1 (en) 2004-03-04
KR20050058454A (ko) 2005-06-16
PL375742A1 (en) 2005-12-12
ZA200501133B (en) 2008-01-30
AU2003255937A1 (en) 2004-03-11
JP2006501238A (ja) 2006-01-12
EP1539127A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
US20070203212A1 (en) Method of treating osteoarthritis
CA2494544A1 (en) Method of treating osteoarthritis
RU2286151C2 (ru) Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
US20040019053A1 (en) Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
US20050026979A1 (en) Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US20040034086A1 (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
US20040034085A1 (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
US20030166706A1 (en) Method of treating osteoarthritis
US20050004196A1 (en) Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such
JP2006503812A (ja) アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−２阻害薬との組み合わせ
US20040023969A1 (en) Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
US20040019055A1 (en) Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued